Interview: Ignasi Biosca, CEO, Reig Jofre, Spain
Prior to joining the family business, Ignasi Biosca spent his career working in online media and internet advertising. Upon becoming CEO of Reig Jofre in 2007, he quickly sought to…
Research in neuroscience has a longstanding tradition in Spain mostly inspired by Nobel Prize winner Santiago Ramón y Cajal and his disciples, for whom the “Instituto Cajal” (IC) was initially conceived in 1934. Five years later the Spanish Government created the National Research Council under the name of Consejo Superior de Investigaciones Cientificas (CSIC) and the IC became one of the first centers of this new Institution. The IC is one of the two CSIC centers fully devoted to research in Neuroscience. The Institute moved to its present location in downtown Madrid in a building of 4,500 m2 in 1989. Currently the IC houses 25 independent research teams and around 200 staff, with operating costs close to 9 K€/year.
From its inception the Cajal Institute has contributed to the advance in Neuroscience and has hosted and formed many of the neuroscientists working now in the different Spanish research and academic centers. Along almost one century of life, the Institute has become a center of worldwide reputation, building on the important contributions of its founder to the present day. Current staff of the Institute has been selected under a tight competitive system according to the high standards of the CSIC. Presently, the institute is organized in two departments: Functional and Systems Neurobiology, and Cellular, Molecular and Developmental Neurobiology, which intend to agglutinate research in all major areas of neuroscience. The focus of the IC research can be comprised in five major lines:
– Mechanisms of neural specification
– The neuro-vascular unit
– Processing of neural signals (a new line of work in neuro-prosthetics and bioengineering is being planned to be incorporated in the near future to reinforce this section)
– Neuroprotection and regeneration
– Systemic modulators of brain function
Contact information:
Cajal Institute (CSIC)
Avenida Doctor Arce 37
28002 Madrid.
Prior to joining the family business, Ignasi Biosca spent his career working in online media and internet advertising. Upon becoming CEO of Reig Jofre in 2007, he quickly sought to…
Xavi Martí, managing director of Lundbeck Spain, discusses how the affiliate responds to the challenge of social stigma surrounding mental diseases and new strategies to open up the company’s portfolio…
Key to improve the Chilean health care system is providing continuous training programs and sharing knowledge with healthcare professionals”, explains Cécile Bassereau, Managing Director B Braun Chile. B. Braun has…
As a leading company in the hospital sector, Roche Spain undoubtedly felt the effects of austerity measures imposed by Spanish health authorities since 2010. Nevertheless, the affiliate has remained in…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Owned completely by the LEO Foundation, LEO Pharma is an extremely patient-centric company focused primarily in the dermatology area. Kristian Hart-Hansen, general manager of LEO Pharma Spain, discusses the challenges…
In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains…
In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains…
Raúl Díaz-Varela is the CEO of Kern Pharma and has served as president of Spain’s generics association AESEG since 2008. He speaks to us about the challenges facing generic companies,…
Jesús Sobrino was appointed general manager of UCB Iberia in 2010, at the same time the pharma market began to seriously contract in Spain. Sobrino discusses adapting to these changes…
PharmaBoardroom first interviewed Erik Lommerde as general manager of Novo Nordisk Netherlands four years ago. In his new role as general manager of Novo Nordisk Spain & Portugal, he discusses…
Invest in Catalonia discuss the Spanish region’s track record when it comes to the pharmaceutical and biotech sectors, where investment is going today in the region, and the factors that…
See our Cookie Privacy Policy Here